Q-omics provides the consensus-scored C6orf62 profile across patient tissues and cancer cell-line models. C6orf62 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, C6orf62 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, C6orf62 RNA expression shows 20,447 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight BLCA, HNSC, and ACC as cancer lineages where C6orf62 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C6orf62 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C6orf62 survival associations across molecular data types. C6orf62 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C6orf62 RNA expression–survival associations across cancer types. High C6orf62 expression shows unfavorable associations in ACC, LGG and KICH, but favorable associations in BLCA, SKCM and KIRC. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for C6orf62 RNA expression.
This table summarizes C6orf62 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for C6orf62. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C6orf62 shows lower tumor expression in KICH and higher tumor expression in HNSC, LIHC, KIRC, BRCA and STAD. The HNSC box plot shows higher C6orf62 RNA expression in tumor versus normal tissue (log2 FC = +0.660, t-test p < 0.001).
This table shows molecular features associated with C6orf62 in patient tissues and cancer cell lines. In patient samples, C6orf62 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, C6orf62 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
